Name of Project: Medication Development for
Stimulant Dependence (MDS): Phase II-Double Blind, Placebo-Controlled
Dose Response Trial of Ondansetron for the Treatment of Methamphetamine
Dependence in Thailand
Principal Investigator: Walter Ling, M.D.
Project Director: Jerry Cunningham-Rathner
Funding Agency: National Institute on Drug Addiction
(NIDA)
Funding Period: March 2003-February 2006
Scope of Project: This study is a randomized
double blind clinical trial of the efficacy and safety of three
wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally
twice per day) to reduce methamphetamine use in subjects with
methamphetamine dependence and to determine the optimal dose of
ondansetron. It’s being conducted at two sites in Thailand
(Chiang Mai and Bangkok). It is hypothesized that ondansetron
treatment, compared to placebo, will be associated with a decrease
in methamphetamine use as measured by proportion of methamphetamine
free urines and self reported non use days.
For more information, contact Walter
Ling.
Last updated - 07/23/2003
Last reviewed - 07/22/2003